“…A total of 20 case reports and one phase I/II study investigating stem-cell therapies in 108 patients (37 women, age 17–75 years, disease duration 1–38 years, follow-up 7–78 months) suffering from CIDP, MMN, and myasthenia gravis were found [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Of these patients, 95 suffered from CIDP, 10 suffered from myasthenia gravis, and one each suffered from MMN, myasthenia gravis and concomitant amyotrophic lateral sclerosis (ALS), and myasthenia gravis and concomitant polymyositis [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 ]. Due to consideration of several case reports, the patients’ symptoms and disease-related disability were highly heterogeneous and scored with different clinical evaluation tools (modified Rankin scale, inflammatory neuropathy cause and treatment score, Rasch-built overall disability scale, medical research council sum score, myasthenia gravis foundation of America score, and myasthenia gravis composite score) [ 104 , 1...…”